BPC-157 & TB-500 (Wolverine Stack) vs Retatrutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BPC-157 & TB-500 (Wolverine Stack)
Known as the 'Wolverine Stack,' this popular combination pairs two powerful healing peptides. BPC-157 and TB-500 work synergistically to promote tissue repair, reduce inflammation, and accelerate recovery from injuries.
Full details →Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Full details →Side-by-Side Comparison
| Aspect | BPC-157 & TB-500 (Wolverine Stack) | Retatrutide |
|---|---|---|
| Mechanism | BPC-157 upregulates growth factor expression and promotes angiogenesis, while TB-500 promotes cell migration and differentiation through actin regulation. Together, they enhance wound healing, reduce scar tissue formation, and support musculoskeletal recovery through complementary pathways. | Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation. |
| Typical Dosage | Typical research protocols: BPC-157 at 250-500mcg daily combined with TB-500 at 2-2.5mg twice weekly during loading phase, then 2mg every 2 weeks for maintenance. | Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials. |
| Administration | Both peptides administered via subcutaneous injection. Some protocols suggest injecting near injury sites for localized effects. Can be injected separately or as a pre-mixed blend. | Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved. |
| Side Effects | Generally well-tolerated. May include mild nausea, temporary fatigue, headache, or localized irritation at injection sites. | Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity. |
| Best For |